Featured Research

from universities, journals, and other organizations

Patients at high risk of recurrences of heart disease: Breakthrough in prevention

Date:
May 24, 2010
Source:
University of Montreal
Summary:
Researchers have announced promising findings of a major clinical study study on VIA-2291 -- a recently developed medication that can effectively reduce inflammation, which can contribute to the formation and progression of atherosclerosis plaque and infarct.

Researchers have announced promising findings of a major clinical study study on VIA-2291 -- a medication developed by Via Pharmaceuticals, a San Francisco-based biotechnology firm, that can effectively reduce inflammation, which can contribute to the formation and progression of atherosclerosis plaque and infarct.

Related Articles


The results of the study, carried out at the Montreal Heart Institute (MHI) by Dr. Jean-Claude Tardif, are now available in the journal Circulation Cardiovascular Imaging. Dr. Tardif is a cardiologist and director of the MHI Research Centre, as well as a professor in the faculty of medicine and holder of the atherosclerosis research chair at the Université de Montréal.

"Up to now, standard treatments for patients with acute coronary syndrome (unstable angina and infarct) have not specifically reduced inflammation, an important component of atherosclerosis. However, research in recent years has allowed us to determine that the presence of inflammation significantly increases the risk of recurrence among these patients. The clinical study was conducted with about 200 patients, and the findings we're publishing show that VIA-2291 may finally offer the solution we need to target and reduce inflammation. In fact, these newly published data strongly support the evaluation of VIA-2291 in larger outcome trials," said Dr. Tardif.

The Montreal Heart Institute's Research Centre directed the study in several hospitals in Canada and the United States as well as analyzed all of the data, including data collected by CAT scans of coronary arteries.

"The publication of this new study attests once again to the excellence of the entire team at the Montreal Heart Institute's Research Centre. While we're clearly satisfied with the findings obtained with VIA-2291, we're even more thrilled at the prospect of taking a big step toward more effective and personalized prevention of cardiovascular disease," concluded Dr. Tardif.


Story Source:

The above story is based on materials provided by University of Montreal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jean-Claude Tardif, Philippe L. L'Allier, Reda Ibrahim, Jean C. Grégoire, Anna Nozza, Mariève Cossette, Simon Kouz, Marc-André Lavoie, Janie Paquin, Tilmann M. Brotz, Rebecca Taub, and Josephine Pressacco. Treatment With 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary Syndrome. Circulation Cardiovascular Imaging, 2010; 3: 298-307 DOI: 10.1161/CIRCIMAGING.110.937169

Cite This Page:

University of Montreal. "Patients at high risk of recurrences of heart disease: Breakthrough in prevention." ScienceDaily. ScienceDaily, 24 May 2010. <www.sciencedaily.com/releases/2010/05/100520141242.htm>.
University of Montreal. (2010, May 24). Patients at high risk of recurrences of heart disease: Breakthrough in prevention. ScienceDaily. Retrieved November 24, 2014 from www.sciencedaily.com/releases/2010/05/100520141242.htm
University of Montreal. "Patients at high risk of recurrences of heart disease: Breakthrough in prevention." ScienceDaily. www.sciencedaily.com/releases/2010/05/100520141242.htm (accessed November 24, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, November 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Winter Can Cause Depression — Here's How To Combat It

Winter Can Cause Depression — Here's How To Combat It

Newsy (Nov. 23, 2014) — Millions of American suffer from seasonal depression every year. It can lead to adverse health effects, but there are ways to ease symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

AFP (Nov. 23, 2014) — The arable district of Kenema in Sierra Leone -- at the centre of the Ebola outbreak in May -- has been under quarantine for three months as the cocoa harvest comes in. Duration: 01:32 Video provided by AFP
Powered by NewsLook.com
Don't Fall For Flu Shot Myths

Don't Fall For Flu Shot Myths

Newsy (Nov. 23, 2014) — Misconceptions abound when it comes to your annual flu shot. Medical experts say most people older than 6 months should get the shot. Video provided by Newsy
Powered by NewsLook.com
Indians Muck in for Cleaner Communities

Indians Muck in for Cleaner Communities

AFP (Nov. 22, 2014) — India's government is urging all citizens to come together in a mass movement to clean the nation -- but will people heed the call? Duration: 02:39 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins